Login / Signup

Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)-a phase III, prospective, multicentre, randomized study: design and methods.

Leonard M CoulibalyStefan SacuPhilipp FuchsHrvoje BogunovicGeorg FaustmannChristian UnterrainerGregor Sebastian ReiterUrsula Margarethe Schmidt-Erfurth
Published in: Eye (London, England) (2022)
EudraCT-Number: 2019-003133-42.
Keyphrases
  • age related macular degeneration
  • phase iii
  • double blind
  • open label
  • clinical trial
  • placebo controlled
  • phase ii
  • machine learning
  • high throughput
  • deep learning
  • high resolution
  • combination therapy
  • cross sectional